EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience

Giulia Cerretti, Alberto Bosio, Giovanni Librizzi, Giovanna Pintacuda, Mario Caccese, Alessandro Salvalaggio, Marco Zoccarato, Alessandro Parisi, Marta Padovan, Marta Maccari, Francesco Cavallin, Luisa Bellu und 7 weitere

Journal of Neuro-Oncology · 2025

DOI: 10.1007/s11060-025-04992-4 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Giulia Cerretti und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Oncology and Gastroenterology, University of Padua, Via Gattamelata n°64, 35128, Padua, Italy. giuliacerretti@gmail.com. Hauptthemen laut MEDLINE: Bevacizumab, Glioblastoma, Brain Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Padova.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Bevacizumab is an anti-angiogenetic treatment that can be used in patients with recurrent glioblastoma, but there are limited and controversial data on the optimal dose and schedule, associated toxicities and survival benefits of different doses.

Methods

A retrospective analysis of patients with recurrent IDH wt glioblastoma treated with bevacizumab at the Veneto Institute of Oncology was performed. Patients received bevacizumab in 2 different schedules (5 mg/kg or 10 mg/kg q2w), as monotherapy or in combination with chemotherapy.

Results

81 patients were analyzed, 33 received bevacizumab 5 mg/Kg, 48 received bevacizumab 10 mg/Kg. Median PFS was 4 months in both patients treated with 5 mg/kg and those treated with 10 mg/kg (p-value=0.08), median OS was 5 months in patients treated with 5 mg/kg and 7 months in those treated with 10 mg/kg (p-value=0.10). There was no difference in the use of steroid therapy between the two groups. The incidence of adverse events was not statistically different.

Conclusions

There was no statistically significant difference in survival, PFS, response, toxicity and steroid reduction between the two different doses. These results may support the use of lower doses of the drug with comparable benefit for patients and with additional advantage in terms of health care costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabGlioblastomaBrain NeoplasmsNeoplasm Recurrence, LocalAntineoplastic Agents, ImmunologicalAngiogenesis InhibitorsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultDose-Response Relationship, DrugFollow-Up Studies

Stichwörter der Autor:innen

AntiangiogenesisBevacizumabBevacizumab doseGlioblastomaRecurrent glioblastomaToxicity

Substanzen

BevacizumabAntineoplastic Agents, ImmunologicalAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Surgery, Oncology and Gastroenterology, University of Padua, Via Gattamelata n°64, 35128, Padua, Italy. giuliacerretti@gmail.com.
  • Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata n°64, 35128, Padua, Italy.
  • Department of Surgery, Oncology and Gastroenterology, University of Padua, Via Gattamelata n°64, 35128, Padua, Italy.
  • Neuroradiology, Department of Neurosciences, University of Padova, Padova, Italy.
  • Padova Neuroscience Center (PNC), University of Padova, Padova, Italy.
  • Radiology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.

Förderung

  • Università degli Studi di Padova

Zitieren

APA

Cerretti, G., Bosio, A., Librizzi, G., Pintacuda, G., Caccese, M., Salvalaggio, A., Zoccarato, M., Parisi, A., Padovan, M., Maccari, M., Cavallin, F., Bellu, L., Pasqualetti, F., Ius, T., Denaro, L., Volpin, F., Coppola, M., Lonardi, S., & Lombardi, G. (2025). Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-025-04992-4

Vancouver

Cerretti G, Bosio A, Librizzi G, Pintacuda G, Caccese M, Salvalaggio A, et al. Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-025-04992-4

BibTeX
@article{Cerretti2025,
  author = {Cerretti, Giulia and Bosio, Alberto and Librizzi, Giovanni and Pintacuda, Giovanna and Caccese, Mario and Salvalaggio, Alessandro and Zoccarato, Marco and Parisi, Alessandro and Padovan, Marta and Maccari, Marta and Cavallin, Francesco and Bellu, Luisa and Pasqualetti, Francesco and Ius, Tamara and Denaro, Luca and Volpin, Francesco and Coppola, Marina and Lonardi, Sara and Lombardi, Giuseppe},
  title = {Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience},
  journal = {Journal of Neuro-Oncology},
  year = {2025},
  doi = {10.1007/s11060-025-04992-4}
}
Kostenlos starten →